Chemosensitization and mitigation of Adriamycin-induced cardiotoxicity using combinational polymeric micelles for co-delivery of quercetin/resveratrol and resveratrol/curcumin in ovarian cancer

Chemosensitization and mitigation of Adriamycin-induced cardiotoxicity using combinational polymeric micelles for co-delivery of quercetin/resveratrol and resveratrol/curcumin in ovarian cancer
复制标题

DOI:
10.1016/j.nano.2019.03.011
复制
发表时间:
2019-07-01
影响因子:
5.4
通讯作者:
Alani, Adam W. G.
Alani, Adam W. G.
中科院分区:
医学2区
文献类型:
--
作者:
Al Fatease, Adel;Shah, Vidhi;Alani, Adam W. G.

文献摘要

被引文献

相似文献

这项工作旨在在健康小鼠和卵巢癌异种移植模型中使用胶束白藜芦醇 (R): 槲皮素 (Q) (mRQ) 或 R: 姜黄素 (C) (mRC) 组合来提高阿霉素 (ADR) 的疗效,同时减轻其心脏毒性。将卵巢癌细胞、ES2-Luc 或 A2780ADR 接种到小鼠(n = 4/组)中,并分为八组。小鼠每周接受 ADR、ADR+mRQ、ADR+mRC 或对照(盐水、空胶束、ADR+EM、mRQ 或 mRC)治疗,持续 4 周。为了评估心脏保护程度,收集血清以确定心肌肌钙蛋白 I (cTnI)。收集心脏组织用于形态学评估和肌酸激酶水平评估。我们的结果表明,mRQ+ADR 在异种移植模型中肿瘤减少方面具有统计学意义。在健康小鼠中,ADR 治疗组的左心室射血分数和缩短分数受到的影响最大。 mRQ 与 ADR 联合给药可以通过化疗增敏来减少 ADR 剂量,同时具有心脏保护作用。 (C) 2019 Elsevier Inc. 保留所有权利。
This work looks to improve the efficacy of Adriamycin (ADR) while mitigating its cardiotoxicity using combinations of micellar resveratrol (R): quercetin (Q) (mRQ) or R: curcumin (C) (mRC) in healthy mice and ovarian cancer xenograft models. Ovarian cancer cells, ES2-Luc, or A2780ADR are inoculated in mice (n =4/group) and sorted into eight cohorts. Mice are treated weekly for 4 weeks with ADR, ADR+mRQ, ADR+mRC, or controls (saline, empty micelles, ADR+EM, mRQ, or mRC). To evaluate the degree of cardioprotection, serum is collected to determine the cardiac Troponin I (cTnI). Cardiac tissue is collected for morphological evaluation and evaluation of creatine kinase levels. Our results indicate that mRQ+ADR is statistically significant in tumor reduction in xenograft models. In healthy mice, the left ventricular ejection fraction and fractional shortening in the ADR treated group is most compromised. Co-administration of mRQ with ADR can reduce ADR dosing through chemosensitization while being cardioprotective. (C) 2019 Elsevier Inc. All rights reserved.